Pope Francis (Credit: X)
Pope Francis injured his right arm after suffering a fall earlier this week. According to the Vatican, while the 88-year-old pontiff did not break his arm, a sling was put on as a precaution. This incident comes just weeks after another fall on December 7, where he hit his chin on a nightstand, resulting in another, visible bruise. The pope's health has been a topic of ongoing speculation due to his age and medical history, which includes long bouts of bronchitis and mobility challenges. Often seen using a wheelchair or a cane, Francis also uses a walker within the Vatican's Santa Marta hotel, where he resides. Notably, his frailty has brought renewed attention to the risks of falls among elderly individuals and the steps one must follow to mitigate such falls.
A study published in Frontiers in Aging Neurosciences people get older, the bone density in the lower back and thigh bone decreases significantly. This raises the risk of osteoporosis (OP). Therefore it becomes pivotal to pay early attention to nutrition, exercise ability, vitamin D levels, and uric acid levels in older individuals to prevent Ostreopsis and mitigate fall risks. The risk of falls and bone injuries among elderly individuals underscores the importance of preventive measures for maintaining bone health and minimizing fall risks.
Elderly, particularly menopausal women, require a daily calcium intake of 1,200 mg, divided into two or more doses. This can be achieved through dietary sources such as dairy and non-dairy products or through supplements like calcium carbonate and calcium citrate. However, total daily calcium intake should not exceed 2,500 mg to avoid potential health risks.
Vitamin D is essential for calcium absorption and bone mineralization. While sunlight exposure helps synthesize vitamin D, older individuals often require supplements due to reduced skin synthesis and the limited availability of foods. Fortified milk and supplements containing 200–600 IU of vitamin D daily are recommended, with higher doses required for those with deficiencies. Severe cases may necessitate high-dose treatments, such as 50,000 IU weekly for up to three months, along with regular monitoring of calcium and vitamin D levels.
Regular exercise is vital for preserving bone mass and reducing fall risk. Weight-bearing activities, strength training, and balance exercises like brisk walking or skipping can enhance bone density and improve coordination. Experts recommend at least 30 minutes of moderate physical activity most days of the week, supplemented by strength training twice weekly. For individuals unable to engage in standard exercise routines, alternatives like vibrating platforms may help maintain bone health.
Falls remain a leading cause of fractures among individuals over 60. Addressing contributing factors such as balance issues, vision problems, and environmental hazards can significantly reduce risks. Preventive measures include regular vision checks, minimizing medications causing dizziness, improving home safety (e.g., installing railings and removing loose rugs), and wearing rubber-soled footwear. Hip protectors may also help mitigate the impact of falls.
Credit: AI
People who are battling anxiety may not be able to access anti-anxiety sold by Whole Foods, a popular brand in the United States. 365 Whole Foods Market Standardized + Full Spectrum Blend Ashwagandha Capsules by Vitality Works were voluntarily recalled recently over possible Salmonella contamination.
According to the Food & Drug Administration, manufacturers found the contamination during routine testing. The potentially contaminated drug has been on shelves since October 20 and will be available for purchase until November 24. Here is everything you need to know about the recall:
Ashwagandha is a popular herbal supplement widely used to help the body manage stress and anxiety.
The recall affects a specific batch of 365 Whole Foods Market Standardized + Full Spectrum Blend Ashwagandha Capsules (120-count size). The pills are sold on Amazon and at Whole Foods outlets. No illnesses have been reported due to the recalled pill so far.
To see if your bottle is part of the recall, check the bottom of the white plastic container for these specific details:
Also read: US FDA Recalls Thousands Of Blood Pressure Drugs Over Excess Drug Levels, Failed Quality Tests
Salmonella is a group of bacteria that can cause a foodborne illness called salmonellosis. While it is most commonly linked to contaminated foods like poultry, eggs, or unpasteurized milk, it can occasionally turn up in dry goods and medicines if raw ingredients are exposed to the bacteria during harvesting or processing.
When someone ingests salmonella, the bacteria irritate the lining of the intestines. Symptoms usually show up anywhere from six hours to six days after exposure. Salmonella infection may cause:
Most healthy people recover within a week without any medical treatment. However, the infection can be much more severe and occasionally dangerous for young children, older adults, and individuals with compromised immune systems.
The bacteria can occasionally enter the bloodstream and cause more severe infections. The CDC has warned that the actual number of infections may be higher than reported because some people recover without seeking medical care or getting tested.
Also read: Amgen & AstraZeneca's New Treatment Combination Cuts Advanced Lung Cancer Death Risk By 58% In Trial
If you have a bottle of these ashwagandha capsules, take a quick look at the lot number. It is recommended to stop taking them immediately if they match the batch number that was recalled.
You could bring it back to the seller and get a refund by bringing your receipt. You could also discard the product safely in the trash if the seller does not accept returns.
If you have already taken these capsules and are feeling healthy, do not panic. Keep monitoring yourself for symptoms of infection. However, if you develop a sudden and persistent fever, severe stomach pain, or signs of a stomach bug in the days after ingesting the capsules, reach out to your healthcare provider.
Credit: iStock
The US Food and Drug Administration (FDA) has announced nationwide recalls of two blood pressure medications over concerns about excess drug levels and manufacturing quality failures.
The recalls involve combination medications prescribed to manage hypertension. The FDA cited concerns that one medication may contain more of an active ingredient than specified, while the other failed quality tests that assess how quickly the drug dissolves in the body.
Also read: US FDA Recalls India-Made BP Drug For The Second Time In 3 Months: Here's Why
1. Viatris blood pressure medication: 21,620 bottles recalled
The FDA has announced a Class III recall of Viatris Inc.'s combination telmisartan and amlodipine tablets because they may contain more telmisartan than specified.
The Class III recall means the use of the affected product is not likely to cause adverse health consequences.
The FDA did not specify how much additional telmisartan the tablets may contain. However, the National Library of Medicine warns that an overdose of this medication could cause low blood pressure, dizziness or a rapid heart rate.
In total, 21,620 bottles of the medication have been recalled.
The recall covers 30-count bottles of telmisartan and amlodipine tablets (40 mg/5 mg) with the following lot codes:
2. Macleods Pharmaceuticals blood pressure medication: 3,744 bottles recalled
The FDA has also recalled 3,744 bottles of another combination blood pressure medication manufactured by Macleods Pharmaceuticals.
The company first initiated the recall on October 7 over "failed dissolution specifications." This means the medication may not release its active ingredients at the required rate after being taken.
If a drug does not dissolve properly, its active ingredients may not be absorbed as intended, potentially affecting its effectiveness. In this case, the medication may not lower blood pressure as expected.
On October 26, the FDA classified the recall as Class II. This means using the affected product may cause temporary or medically reversible adverse health consequences, although serious health problems are unlikely.
The recall covers:
Read More: Mounjaro, Zepbound Ingredient Recalled In US Over Sterility Concerns
The FDA advises patients not to stop taking their medication without consulting their healthcare provider, as abruptly discontinuing blood pressure treatment may pose additional health risks.
If you have any of the affected products, contact your doctor or pharmacist for guidance on whether you should continue taking them or switch to an alternative.
For the Macleods Pharmaceuticals medication, the FDA did not issue a separate news release. Its enforcement report states that letters were sent to notify businesses and individuals who may have the affected products.
Patients should consult their healthcare provider before making any changes to their medication routine.
Credit: iStock
A child recently died in Lewis County amid an ongoing measles outbreak, marking New York state's first measles-related death in more than 30 years. The New York State Department of Health and Lewis County Public Health confirmed the death in a joint statement on November 2.
Officials did not release more information about the child or the circumstances surrounding the death to protect the family's privacy.
The death comes as measles cases continue to rise across the United States. New York had recorded 178 cases in 2026 as of October 24, including eight in New York City, according to health officials.
Last month, Governor Kathy Hochul declared a state disaster emergency. The order gave registered nurses the authority to order specimen collection and testing for measles cases.
The outbreak in New York is part of a wider resurgence of measles across the country. The US Centers for Disease Control and Prevention (CDC) reported 4,852 confirmed cases as of October 29, 2026, the highest annual total since 1991.
In an exclusive interview with HealthandMe, Dr Paul Offit, paediatrician and director of the Vaccine Education Center at Children’s Hospital of Philadelphia and former member of the CDC’s Advisory Committee on Immunization Practices, said that the reported number of measles cases in the US could underestimate the actual scale of transmission. “You can assume that's off by a factor of at least five."
The CDC said 96% of confirmed cases this year were linked to outbreaks. It has also reported that at least 96% of cases have occurred among people who were unvaccinated.
Declining vaccination coverage has contributed to the growing measles transmission. During the 2025-2026 school year, 92.4% of US kindergarteners had received the measles, mumps and rubella (MMR) vaccine, below the 95% coverage level generally needed to maintain community protection.
Measles is a highly contagious viral infection that spreads through the air when an infected person coughs or sneezes. The virus can remain infectious in the air for up to two hours after an infected person has left a space.
Early symptoms include high fever, cough, runny nose and red, watery eyes. Small white spots called Koplik spots may appear inside the mouth, followed by a rash that begins on the face and spreads down the body.
While many people recover, measles can cause serious complications, including pneumonia and encephalitis, or inflammation of the brain. These complications can lead to hospitalisation and, in some cases, death. Young children, pregnant women and people with weakened immune systems are vulnerable to the illness.
The CDC recommends two doses of the MMR vaccine. The first is given between 12 and 15 months of age, while the second is recommended between four and six years.
One dose is approximately 93% effective against measles infection, while two doses are about 97% effective, according to the CDC.
Infants aged six to 11 months who live in or are travelling to areas with a high risk of measles exposure may be advised to receive an early dose. However, this dose does not replace the two routine doses recommended after the child's first birthday..
© $2026 Times Horizon Private Limited